Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Liver Diseases

Free Subscription 13.04.2026 6 BMC Gastroenterol 2 Dig Dis Sci 1 Gut 2 Hepatology 1 J Comput Assist Tomogr 3 J Gastroenterol Hepatol 3 J Hepatol 1 J Pediatr 3 Lancet 2 Oncogene 2 PLoS One 2 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Gastroenterol

1. WAKUI N, Ogino Y, Nagumo H, Watanabe N, et al
   Pemafibrate therapy increases serum zinc levels in patients with metabolic dysfunction-associated steatohepatitis: a prospective study.
   BMC Gastroenterol. 2026 Apr 9. doi: 10.1186/s12876-026-04806.
   PubMed         Abstract available
   
   
2. LIU X, Li H, Wang F, Su K, et al
   Correction: Transhepatectomy combined with arterial chemoembolization and transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a clinical prognostic analysis.
   BMC Gastroenterol. 2026;26:216.
   PubMed        
   
   
3. KIM RG, Ballantyne A, Lancaster E, Galyean P, et al
   Social needs screening in hepatology clinic: a qualitative study of patient experience.
   BMC Gastroenterol. 2026 Apr 7. doi: 10.1186/s12876-026-04797.
   PubMed        
   
   
4. TAPPER EB, Ryan T, Lewandowski D, Winer-Jones JP, et al
   Burden of metabolic dysfunction-associated steatohepatitis, with and without metabolic syndrome, obesity, or diabetes.
   BMC Gastroenterol. 2026 Apr 6. doi: 10.1186/s12876-026-04787.
   PubMed         Abstract available
   
   
5. XIAO Z, Li X, Dong S, Zhou F, et al
   Risk prediction models for hepatic encephalopathy in patients with liver cirrhosis: a systematic review and meta-analysis.
   BMC Gastroenterol. 2026 Apr 6. doi: 10.1186/s12876-026-04781.
   PubMed        
   
   
6. SONG Y, Ren R, Li R, Zou M, et al
   Determinants and cost composition of hospitalization for EGVB in decompensated cirrhosis.
   BMC Gastroenterol. 2026 Apr 6. doi: 10.1186/s12876-026-04775.
   PubMed        
   
   

   
   Dig Dis Sci

7. RAMJI HF, Gatiganti A, Janwadkar A, Lampenfeld J, et al
   The Impact of Specific Prompt Engineering Techniques on the Readability of LLM-Generated Patient Materials in Gastroenterology and Hepatology.
   Dig Dis Sci. 2026 Apr 9. doi: 10.1007/s10620-026-09879.
   PubMed         Abstract available
   
   
8. LIM RY, Low PJS, Lim WH, Selvakumar A, et al
   Impact of Transjugular Intrahepatic Portosystemic Shunt on Waitlist and Post-transplant Outcomes in Liver Transplant Candidates.
   Dig Dis Sci. 2026 Apr 4. doi: 10.1007/s10620-026-09825.
   PubMed         Abstract available
   
   

   
   Gut

9. MA H, Cao T, Zhang F, Sun D, et al
   Nuclear Pirin promotes HCC by acting as a key inflammation-facilitating factor.
   Gut. 2026;75:1016-1029.
   PubMed         Abstract available
   
   

   
   Hepatology

10. NAHON P, Ziol M, Pan L, Portal JJ, et al
    Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with BCLC a hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial).
    Hepatology. 2026 Apr 8. doi: 10.1097/HEP.0000000000001764.
    PubMed         Abstract available
    
    
11. ALLEGRETTI AS, Cullaro G, Kwo P, Pyrsopoulos N, et al
    OCE-205, a selective V1a receptor mixed agonist-antagonist, for the treatment of hepatorenal syndrome-acute kidney injury: A phase 2 randomized trial.
    Hepatology. 2026 Apr 8. doi: 10.1097/HEP.0000000000001765.
    PubMed         Abstract available
    
    

    
    J Comput Assist Tomogr

12. COOK ER, Jha RC
    The Hepatic Arterial Buffer Response: A Unifying Concept for Understanding Perfusional Alterations of the Liver.
    J Comput Assist Tomogr. 2026 Apr 6. doi: 10.1097/RCT.0000000000001860.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

13. MEHRISH FNU, Khan T, Moazzam M
    Clinical Integration of Novel Non-Invasive Biomarkers in Hepatology: Bridging Statistical Promise and Bedside Utility.
    J Gastroenterol Hepatol. 2026 Apr 9. doi: 10.1111/jgh.70390.
    PubMed        
    
    
14. WANG ZV, Boumelhem BB, Pennell T, Bachovchin WW, et al
    A Novel Fibroblast Activation Protein-Based Algorithm to Assess Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2026;41:1311-1322.
    PubMed         Abstract available
    
    
15. SOUZA M, Amaral MJM, Moura FS, Lima LCV, et al
    Epidemiology and Clinical Characteristics of Fatty Pancreas Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review.
    J Gastroenterol Hepatol. 2026;41:1107-1115.
    PubMed         Abstract available
    
    

    
    J Hepatol

16. REIG M, Sanduzzi-Zamparelli M, Forner A, Rimola J, et al
    Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].
    J Hepatol. 2026 Apr 4:S0168-8278(26)00126-1. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    
17. ZHANG Z, Lu S, Shu Y, Zhang S, et al
    Chromatin remodeling in pericentral hepatocytes modulates MASH through CYP450 activity.
    J Hepatol. 2026 Apr 2:S0168-8278(26)00190-X. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
18. FENG D, Rodrigues RM, Gao B
    IL-22 unlocks large-scale in vitro hepatocyte expansion via STAT3 activation.
    J Hepatol. 2026 Apr 2:S0168-8278(26)00189-3. doi: 10.1016/j.jhep.2026.
    PubMed        
    
    

    
    J Pediatr

19. SUNDARAM SS, Kelsey M, Nadeau KJ, Cooper E, et al
    Resolution of Biochemical and Histologic Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adolescents with Severe Obesity following Metabolic Bariatric Surgery.
    J Pediatr. 2025 Dec 22:114944. doi: 10.1016/j.jpeds.2025.114944.
    PubMed         Abstract available
    
    

    
    Lancet

20. LIANG F, Zhou S, Wang Z, Fan J, et al
    Perioperative immunotherapy for resectable hepatocellular carcinoma - Authors' reply.
    Lancet. 2026;407:1334.
    PubMed        
    
    
21. LI Z, Tang Y
    Perioperative immunotherapy for resectable hepatocellular carcinoma.
    Lancet. 2026;407:1332.
    PubMed        
    
    
22. JIN W, Xue M, Luo S
    Perioperative immunotherapy for resectable hepatocellular carcinoma.
    Lancet. 2026;407:1332-1334.
    PubMed        
    
    

    
    Oncogene

23. SHEN Z, Yang Y, Mao T, Wu F, et al
    Plasmin promotes hepatocellular carcinoma invasion and metastasis via CXCR4-mediated activation of PI3K/AKT/mTOR signaling.
    Oncogene. 2026 Apr 9. doi: 10.1038/s41388-026-03775.
    PubMed         Abstract available
    
    
24. JIAO Q, Ren Y, Su X, Li Z, et al
    SETDB2 induces abnormal SHP-1 splicing and promotes immunosuppression in hepatocellular carcinoma.
    Oncogene. 2026 Apr 7. doi: 10.1038/s41388-026-03759.
    PubMed         Abstract available
    
    

    
    PLoS One

25. SAEKI C, Oikawa T, Kanai T, Kiryu S, et al
    Clinical usefulness of serum autotaxin levels for predicting decompensation development and prognosis in patients with compensated cirrhosis.
    PLoS One. 2026;21:e0347310.
    PubMed         Abstract available
    
    
26. LIANG J, Song X, Liu Y, Yang G, et al
    IGF1/IGF-1R promotes hepatocellular carcinoma progression by activating the Akt/GSK-3beta pathway.
    PLoS One. 2026;21:e0346926.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

27. OYABU M, Sakaue M, Kubo A, Yoshioka K, et al
    Loss of FoxO in skeletal muscle leads to disrupted muscle metabolism and exacerbates starvation-induced hepatic steatosis.
    Proc Natl Acad Sci U S A. 2026;123:e2600036123.
    PubMed         Abstract available
    
    
28. ZENG W, Liu CC, Li S, Zhou Y, et al
    Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test.
    Proc Natl Acad Sci U S A. 2026;123:e2518347123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum